Bayer & Janssen v. Apotex: Cardiovascular Patent Dispute Dismissed With Prejudice After 3 Years
Bayer AG and Janssen Pharmaceuticals filed suit against Canadian generic manufacturer Apotex in the Delaware District Court, asserting US10828310B2 covering methods of reducing cardiovascular event risk. After 1,112 days of litigation, all claims and counterclaims were dismissed with prejudice by stipulation — each party bearing its own legal costs.
Branded-generic cardiovascular patent standoff ends in bilateral dismissal
On 14 December 2022, Bayer AG and Janssen Pharmaceuticals, Inc. filed an infringement action in the District of Delaware against Apotex Inc. and Apotex Corp., asserting US10828310B2, a patent directed to methods of reducing the risk of cardiovascular events. The case, assigned to Judge Richard G. Andrews, is consistent with standard Hatch-Waxman ANDA litigation in which branded pharmaceutical plaintiffs seek to block a generic entrant from launching before patent expiry.
On 30 December 2025, the parties filed a stipulated dismissal under Federal Rules of Civil Procedure 41(a)(1) and 41(c), extinguishing all of Plaintiffs’ claims against Apotex and all of Apotex’s counterclaims and defenses against Plaintiffs — each dismissed with prejudice. No costs, disbursements, or attorneys’ fees were awarded to either side. A dismissal with prejudice bars any future refiling of the same claims, making the resolution final and binding on both parties.
The 1,112-day duration — roughly three years — suggests the parties engaged in substantive litigation before reaching resolution, though the public record does not disclose whether a commercial settlement or licensing arrangement underpins the stipulation. The mutual with-prejudice dismissal and absence of any cost award is consistent with a negotiated resolution rather than a litigated outcome. The specific terms driving the parties to agree — including any launch date commitments or royalty arrangements — remain confidential and are not reflected in the court docket.
Filing to Dismissed with Prejudice in 1112 days
1,112 days — above the ~730-day median for ANDA patent cases in Delaware District Court
Dismissed with prejudice by stipulation: what the ruling means for both parties
Rule 41 stipulated dismissal: a final, bilateral exit from litigation
A dismissal with prejudice under Rule 41(a)(1) and 41(c) is a final adjudication on the merits for preclusion purposes. Because both Plaintiffs’ claims and Apotex’s counterclaims are dismissed with prejudice, neither side may reinitiate the same dispute in any U.S. federal court. This is the strongest form of voluntary dismissal — it operates as a permanent bar to re-litigation of the asserted patent against this defendant.
Final and bindingUS10828310B2 survives unchallenged — but enforcement window narrows
Because Apotex’s counterclaims — which typically include invalidity and unenforceability defenses in Hatch-Waxman litigation — were also dismissed with prejudice, Bayer and Janssen avoid an adverse validity ruling on US10828310B2. The patent’s enforceability against other potential generic filers remains intact. However, Plaintiffs forego any injunctive relief or damages from Apotex, suggesting either a negotiated entry date or a commercial resolution not on the public record.
Patent validity preservedApotex exits litigation permanently — market access terms undisclosed
Apotex’s dismissal with prejudice of its counterclaims — including likely invalidity challenges — means the company cannot re-litigate patent validity or non-infringement against Bayer and Janssen for this product. In practice, ANDA defendants reaching this outcome typically do so as part of a settlement that may include an agreed commercial launch date. The absence of a cost award and the bilateral structure of the dismissal is consistent with a negotiated resolution rather than an admission of infringement.
Future challenge barredCardiovascular generic entry: timeline and competitive dynamics remain private
For the broader oral anticoagulant and cardiovascular pharmaceutical sector, this outcome maintains the status quo on US10828310B2 without a public merits ruling. Competitors and other ANDA filers cannot leverage an Apotex invalidity finding as prior art in their own proceedings. The confidential resolution means the patent retains full blocking potential in subsequent Paragraph IV challenges, though the 30-month stay clock and any agreed entry dates negotiated with Apotex are not publicly known.
Patent blocking power intactFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Bayer AG | Company | Global pharmaceutical group — holder of US10828310B2 covering cardiovascular event risk reductionSearch in Eureka ↗ |
| Co-Plaintiff | Janssen Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Bayer AG | Company | Search in Eureka ↗ |
| Defendant | Apotex, Inc. | Company | Canadian-headquartered generic pharmaceutical manufacturer and its U.S. distribution armSearch in Eureka ↗ |
| Co-Defendant | Apotex Corp. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Derek James Fahnestock | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff counsel | Rodger Dallery Smith , II | Attorney | Counsel for Bayer AGSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Bayer AGSearch in Eureka ↗ |
| Defendant counsel | Brian Sodikoff | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant counsel | Rachel L. Schweers | Attorney | Counsel for Apotex, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris James LLP | Law Firm | Representing Apotex, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation dismisses all claims, counterclaims, and defenses with prejudice on both sides — a bilateral, final resolution. The inclusion of Apotex’s counterclaims (typically invalidity and non-infringement) in the with-prejudice dismissal is significant: it prevents the factual and legal record developed during three years of litigation from being used as the basis for any future challenge. The ‘each party bears own costs’ clause is characteristic of negotiated Hatch-Waxman resolutions and suggests neither party achieved a clear litigation victory.
US10828310B2 — Methods of reducing cardiovascular event risk
US10828310B2, filed under application number US16/264032, claims methods directed to reducing the risk of cardiovascular events — a therapeutic use patent consistent with the late-lifecycle protection strategy commonly applied to blockbuster oral anticoagulant products. Method-of-treatment patents in this category protect the clinical indication and dosing rationale rather than the compound itself, extending enforceable exclusivity beyond the composition patent expiry and covering the specific therapeutic benefit labelled in the approved product.
For the cardiovascular pharmaceutical sector, method-of-treatment patents on risk reduction indications are commercially significant because they cover the labelled use that physicians and payers rely on — making generic substitution commercially difficult even after compound patents expire. Any generic manufacturer seeking to launch a cardiovascular product with a Paragraph IV certification against a method-of-treatment patent of this type must either design around the claimed method or challenge validity, both of which carry material commercial and litigation risk. The survival of US10828310B2 without an adverse ruling strengthens Bayer and Janssen’s position against subsequent challengers.
Should you run an FTO against US10828310B2?
Any company developing or commercialising an oral anticoagulant or cardiovascular risk-reduction therapy — whether as an ANDA filer, a branded follow-on, or a combination product developer — should assess exposure to US10828310B2. The patent’s method-of-treatment claims covering cardiovascular event risk reduction are broad enough to implicate a range of therapeutic approaches. The absence of a court-issued invalidity ruling means the patent’s claim scope has not been judicially narrowed, and the with-prejudice dismissal of Apotex’s counterclaims removes a potential source of prior art arguments.
PatSnap Eureka’s FTO Search Agent can rapidly map US10828310B2’s claim language against your product’s therapeutic indication, dosing regimen, and labelling strategy — identifying freedom-to-operate gaps and close prior art before you commit to an ANDA filing or a new clinical program. Eureka surfaces related patents in Bayer and Janssen’s cardiovascular portfolio, flags pending continuation applications, and benchmarks claim scope against the prosecution history, enabling your IP and regulatory teams to make informed go/no-go decisions.
Run a freedom-to-operate analysis on US10828310B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman cardiovascular patent cases in Delaware District Court
Cases involving method-of-treatment patents for cardiovascular risk reduction before the Delaware District Court, including comparable ANDA infringement actions and stipulated dismissal outcomes.
What this case signals for the cardiovascular pharmaceutical IP landscape
A three-year standoff ending in bilateral with-prejudice dismissal reflects calculated risk management — not an admission — on both sides.
With-prejudice structure shields patent from Apotex’s invalidity record
By ensuring Apotex’s counterclaims are dismissed with prejudice, Bayer and Janssen prevent any invalidity arguments developed during discovery from entering the public record as adjudicated findings. Subsequent ANDA filers face the same patent with no adverse validity precedent to rely on — a strategically valuable outcome for the patent holder.
Three-year duration signals substantive engagement before settlement
Cases resolved by stipulated dismissal after 1,112 days typically involve completed claim construction, substantial discovery, and potentially expert proceedings. This suggests the parties had sufficient information to assess litigation risk and negotiate terms — pointing to a commercially driven resolution rather than an early capitulation by either side.
Bayer v Apotex — key questions answered
The dismissal with prejudice means all of Plaintiffs’ infringement claims and all of Apotex’s counterclaims — including invalidity defenses — are permanently extinguished. Neither party may refile the same claims in any U.S. court. The resolution is final and operates as a bar to re-litigation of US10828310B2 between these specific parties.
The case asserted US10828310B2, filed under application number US16/264032. The patent covers methods of reducing the risk of cardiovascular events — a method-of-treatment claim consistent with late-lifecycle protection strategies for oral anticoagulant products in the cardiovascular therapeutic area.
Co-plaintiff structures in Hatch-Waxman litigation typically reflect joint ownership or exclusive licensing arrangements over the asserted patent. Both Bayer AG and Janssen Pharmaceuticals were named plaintiffs, suggesting co-ownership or a co-exclusive licensing interest in US10828310B2 that gave both entities standing to enforce the patent against Apotex’s ANDA filing.
No. The stipulation expressly provides that all parties shall bear their own costs, disbursements, and attorneys’ fees. No fee-shifting was ordered or agreed. This outcome is typical of negotiated Hatch-Waxman resolutions and does not suggest either party was found to have litigated in bad faith or achieved a clearly superior result.
In Hatch-Waxman litigation, defendants typically assert counterclaims for invalidity and non-infringement. Dismissing those with prejudice means Apotex cannot later assert those invalidity arguments against Bayer or Janssen for this patent. It also prevents any invalidity findings from entering the public record, leaving US10828310B2 with no adverse judicial precedent — maintaining its full blocking potential against other generic challengers.
PatSnap Eureka searches patents and litigation data to answer instantly.